About: Clinical performance of different SARS‐CoV‐2 IgG antibody tests

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical performance of different SARS‐CoV‐2 IgG antibody tests Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical performance of different SARS‐CoV‐2 IgG antibody tests
Creator	Ciesek, Sandra Rabenau, Holger Holger, F Rabenau, Westhaus, Sandra Kohmer, Niko Rühl, Cornelia
source	Medline; PMC
abstract	SARS‐CoV‐2 serological assays are urgently needed for rapid diagnosis, contact tracing and for epidemiological studies. So far, there is limited data on how commercially available tests perform with real patient samples and if positive tested samples show neutralizing abilities. Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS‐CoV‐2 IgG and Vircell COVID‐19 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID‐19 IgG/IgM Rapid Test Device) and two in‐house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)). We tested follow up serum/plasma samples of individuals PCR‐diagnosed with COVID‐19. Most of the SARS‐CoV‐2 samples were from individuals with moderate to severe clinical course, who required an in‐patient hospital stay. For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5‐9) and from 93.8 to 100% for the later period (days 10‐18). With exception of one sample, all positive tested COVID‐19 follow up‐samples, using the commercially available assays examined (including the in‐house developed IFA), demonstrated neutralizing properties in the PRNT. Regarding specificity, some samples of endemic coronavirus (HCoV‐OC43, HCoV‐229E) and Epstein Barr virus (EBV) infected individuals cross‐reacted in the ELISA assays and IFA, in one case generating a false positive result. This article is protected by copyright. All rights reserved.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1002/jmv.26145
bibo:pmid	32510168
has license	no-cc
sha1sum (hex)	b681e72b2af409e35dd89c384eef884c11515708
schema:url	https://doi.org/10.1002/jmv.26145
resource representing a document's title	Clinical performance of different SARS‐CoV‐2 IgG antibody tests
has PubMed Central identifier	PMC7300776
has PubMed identifier	32510168
schema:publication	J Med Virol
resource representing a document's body	covid:b681e72b2af409e35dd89c384eef884c11515708#body_text
is schema:about of	named entity 'in-patient' named entity 'period' named entity 'Article' named entity 'Focusing' named entity 'hospital' named entity 'generating' named entity 'assays' named entity 'EBV' named entity 'IgG' named entity 'Epstein Barr virus' named entity 'With' named entity 'neutralizing' named entity 'IgG' named entity 'test' named entity 'OC43' named entity 'DATA' named entity 'ARTICLE' covid:arg/b681e72b2af409e35dd89c384eef884c11515708 named entity 'IFA' named entity 'demonstrate' named entity 'samples' named entity 'SARS-CoV-2' named entity 'infection' named entity 'samples' named entity 'sample' named entity 'copyright' named entity 'early' named entity 'tested' named entity 'assays' named entity 'individuals' named entity 'data' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'in-patient' named entity 'COVID' named entity 'COVID' named entity 'virus' named entity 'endemic' named entity 'PRNT' named entity 'COVID-19' named entity 'serological' named entity 'PRNT' named entity 'plasma' named entity 'IgG/IgM' named entity 'PCR' named entity 'IgG antibody' named entity 'SARS-CoV-2' named entity 'Wuhan' named entity 'Rapid Test' named entity 'immunofluorescence assay' named entity 'betacoronaviruses' named entity 'Hangzhou' named entity 'SARS-CoV-2' named entity 'titer' named entity 'EBV' named entity 'Rajendran' named entity 'WHO' named entity 'IgG antibodies' named entity 'coronaviruses' named entity 'Vero cells' named entity 'spike (S) protein' named entity 'causative agent' named entity 'HCoV-229E' named entity 'antibody' named entity 'CMV' named entity 'Nucleic acid amplification' named entity 'cross-reacting' named entity 'serum or plasma' named entity 'Convalescent plasma' named entity 'IgG antibodies' named entity 'gold standard' named entity 'glycoprotein' named entity 'SARS-CoV-2' named entity 'protein' named entity 'cross-reactivity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software